International Reference Pricing Reforms

Canada’s plan to revise reference basket In a bid to reduce medicine prices in Canada, the Canadian Minister of Health announced the revision of the reference basket for international reference pricing (IRP). Medicines prices in Canada are regulated by the federal government, through the PMPRB (Patented Medicine Prices Review Board). The current reference rule used … More International Reference Pricing Reforms

Egypt: Drug Price Hikes Highlight Market Volatility

With the largest population in the Middle East and North Africa region, Egypt has attracted a strong presence from multinational pharmaceutical companies. However, current turmoil over drug shortages and drug price hikes underscores the volatility of a market characterised by high out-of-pocket spending. Amid the economic instability that followed the 2011 Arab Spring, President Abdel-Fattah … More Egypt: Drug Price Hikes Highlight Market Volatility

AMNOG and the German Reforms: What Will Change?

By Preeti Patel and Sophie Schmitz on Oct 3, 2016  We analyze recent changes in Germany’s pharmaceutical legislation & implications for the industry. Germany is typically prioritized by the pharmaceutical industry: it remains a market with relatively high drug prices, offers extensive commercial opportunities and has an important position as an international reference country to … More AMNOG and the German Reforms: What Will Change?